- Home
- SRRK
as 02-21-2025 4:00pm EST
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
Upcoming Earnings Alert:
Get ready for potential market movements as Scholar Rock Holding Corporation SRRK prepares to release earnings report on 27 Feb 2025.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 4.2B | IPO Year: | 2018 |
| Target Price: | $40.43 | AVG Volume (30 days): | 771.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.76 - $46.98 | Next Earning Date: | 02-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Feb 18 '25 | Sell | $37.33 | 72,645 | $2,714,767.40 | 131,286 | |
| Parlavecchio Caryn | SRRK | CHRO | Feb 18 '25 | Sell | $36.83 | 5,296 | $195,046.38 | 140,258 | |
| Myles Edward H | SRRK | COO & CFO | Feb 18 '25 | Sell | $36.83 | 7,809 | $287,597.66 | 140,740 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Jan 16 '25 | Sell | $44.20 | 7,347 | $324,716.83 | 131,286 | |
| Parlavecchio Caryn | SRRK | CHRO | Jan 16 '25 | Sell | $44.20 | 6,434 | $284,364.78 | 140,258 | |
| Backstrom Jay T. | SRRK | CHIEF EXECUTIVE OFFICER | Jan 16 '25 | Sell | $44.20 | 22,308 | $985,951.14 | 330,363 | |
| Ho Junlin | SRRK | GENERAL COUNSEL | Jan 16 '25 | Sell | $44.20 | 9,039 | $399,498.49 | 195,037 | |
| Myles Edward H | SRRK | COO & CFO | Jan 16 '25 | Sell | $44.20 | 12,539 | $554,188.69 | 140,740 | |
| Marantz Jing L. | SRRK | CHIEF MEDICAL OFFICER | Jan 16 '25 | Sell | $44.20 | 5,655 | $249,935.17 | 67,200 | |
| Sacco Tracey | SRRK | Chief Commercial Officer | Jan 16 '25 | Sell | $44.20 | 3,890 | $171,927.11 | 45,395 |
Latest Scholar Rock Holding Corporation News
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
MT Newswires
2 days ago
Scholar Rock Holding Insider Sold Shares Worth $676,622, According to a Recent SEC Filing
Business Wire
8 days ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
12 days ago
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025
MT Newswires
24 days ago
Scholar Rock Files US FDA Application for Apitegromab in Spinal Muscular Atrophy
MT Newswires
24 days ago
Scholar Rock Names Lisa Wyman as Chief Technical, Quality Officer, COO Role to Be Eliminated
Business Wire
24 days ago
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
Business Wire
24 days ago
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
Compare SRRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.